Mr. Chair, as I noted, the government has invested to strengthen biomanufacturing. A number of critical investments have been made, including in regard to future pandemic preparedness, but more broadly it's all components, from research through to fill and finish of product.
We have a strong generic industry that continues to grow. We are working to further strengthen innovator and domestic biomanufacturing throughout the entire chain, and we are looking at critical medicines that could be at future risk to make sure that we look at multiple strategies to address and preclude future shortages.